Biogen CEO bets on Alzheimer’s drug, pipeline to return to growth
By Manas Mishra (Reuters) -Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer’s disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth. Industry veteran Viehbacher joined the U.S. biotech in November, at a time when sales …
Biogen CEO bets on Alzheimer’s drug, pipeline to return to growth Read More »